- 1、本文档共58页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Copyright © National Comprehensive Cancer Network 2010. All rights reserved. “NCCN”, the NCCN logo, and “National Comprehensive Cancer Network” are
registered trademarks of the National Comprehensive Cancer Network.
The Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer Guideline 2010 is the Chinese adapted version of NCCN Clinical Practice
Guidelines in Oncology-Ovarian Cancer Guideline, V.2.2010 as permitted and endorsed by NCCN. It is the collaborative outcome of the National Comprehensive
Cancer Network and Chinese key opinion leaders of the field.
The original guideline and Chinese edition are both available at: http ://www.nccn .org. To view the most recent and complete version of the guideline, go online to
. These Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN.
These Guidelines are a work in progress that will be refined as often as new significant data becomes available. The NCCN Guidelines are a statement of consensus
of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN guideline is expected to use
independent medical judgment in the context of individual clinical circumstance to determine any patients care or treatment. The National Comprehensive Cancer
Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
This publication should not be used for commercial purpose. It is provided for free to Chinese medical professions with the support of the unrestrictive educational
grant of GlaxoSmithKline (China) Investment Co., Ltd. which exerts no influence to the formation of the Chinese edition of NCCN Clinical Practice Guidelines in
Oncology-Ovarian Cancer Guideline 2010.
NCCN ® 肿瘤学临床
文档评论(0)